Update on the issues of HIV vaccine development

Barton F. Haynes, Shannon Bandy Putman, Jason B. Weinberg

Research output: Contribution to journalArticle

Abstract

Major scientific obstacles blocking the development of a successful preventive HIV vaccine are the extraordinary variability of HIV, the lack of an exact animal model of HIV-induced AIDS, and the lack of understanding of the correlates of positive immunity to HIV. Current HIV vaccines containing the HIV gp120 envelope have been tested in phase I and II trials but they have had a major limitation of neutralizing only T-cell tropic laboratory-adapted HIV strains grown in T-cell lines, but not neutralizing HIV primary isolates. Phase III trials of monovalent HIV gp120 envelope vaccines are being planned in the US and Thailand, but concern has been raised that recombinant monovalent gp120 may not be an appropriate immunogen for an efficious HIV vaccine. Because the immune response is probably responsible for controlling the viral load in some long-term suvivors of HIV infection, studies are now being carried out to induce similar immunity against a broad spectrum of strains of HIV primary isolates with targeted HIV experimental immunogens.

Original languageEnglish (US)
Pages (from-to)39-41
Number of pages3
JournalAnnals of Medicine
Volume28
Issue number1
StatePublished - Feb 1996
Externally publishedYes

Fingerprint

AIDS Vaccines
HIV
HIV Envelope Protein gp120
Immunity
T-Lymphocytes
Thailand
Viral Load
HIV Infections
Acquired Immunodeficiency Syndrome
Vaccines
Animal Models
Cell Line

Keywords

  • AIDS
  • Animal models
  • Immunization
  • Pathogenesis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Haynes, B. F., Putman, S. B., & Weinberg, J. B. (1996). Update on the issues of HIV vaccine development. Annals of Medicine, 28(1), 39-41.

Update on the issues of HIV vaccine development. / Haynes, Barton F.; Putman, Shannon Bandy; Weinberg, Jason B.

In: Annals of Medicine, Vol. 28, No. 1, 02.1996, p. 39-41.

Research output: Contribution to journalArticle

Haynes, BF, Putman, SB & Weinberg, JB 1996, 'Update on the issues of HIV vaccine development', Annals of Medicine, vol. 28, no. 1, pp. 39-41.
Haynes, Barton F. ; Putman, Shannon Bandy ; Weinberg, Jason B. / Update on the issues of HIV vaccine development. In: Annals of Medicine. 1996 ; Vol. 28, No. 1. pp. 39-41.
@article{0318db66bb104342a44312f53dfcf9b8,
title = "Update on the issues of HIV vaccine development",
abstract = "Major scientific obstacles blocking the development of a successful preventive HIV vaccine are the extraordinary variability of HIV, the lack of an exact animal model of HIV-induced AIDS, and the lack of understanding of the correlates of positive immunity to HIV. Current HIV vaccines containing the HIV gp120 envelope have been tested in phase I and II trials but they have had a major limitation of neutralizing only T-cell tropic laboratory-adapted HIV strains grown in T-cell lines, but not neutralizing HIV primary isolates. Phase III trials of monovalent HIV gp120 envelope vaccines are being planned in the US and Thailand, but concern has been raised that recombinant monovalent gp120 may not be an appropriate immunogen for an efficious HIV vaccine. Because the immune response is probably responsible for controlling the viral load in some long-term suvivors of HIV infection, studies are now being carried out to induce similar immunity against a broad spectrum of strains of HIV primary isolates with targeted HIV experimental immunogens.",
keywords = "AIDS, Animal models, Immunization, Pathogenesis",
author = "Haynes, {Barton F.} and Putman, {Shannon Bandy} and Weinberg, {Jason B.}",
year = "1996",
month = "2",
language = "English (US)",
volume = "28",
pages = "39--41",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Update on the issues of HIV vaccine development

AU - Haynes, Barton F.

AU - Putman, Shannon Bandy

AU - Weinberg, Jason B.

PY - 1996/2

Y1 - 1996/2

N2 - Major scientific obstacles blocking the development of a successful preventive HIV vaccine are the extraordinary variability of HIV, the lack of an exact animal model of HIV-induced AIDS, and the lack of understanding of the correlates of positive immunity to HIV. Current HIV vaccines containing the HIV gp120 envelope have been tested in phase I and II trials but they have had a major limitation of neutralizing only T-cell tropic laboratory-adapted HIV strains grown in T-cell lines, but not neutralizing HIV primary isolates. Phase III trials of monovalent HIV gp120 envelope vaccines are being planned in the US and Thailand, but concern has been raised that recombinant monovalent gp120 may not be an appropriate immunogen for an efficious HIV vaccine. Because the immune response is probably responsible for controlling the viral load in some long-term suvivors of HIV infection, studies are now being carried out to induce similar immunity against a broad spectrum of strains of HIV primary isolates with targeted HIV experimental immunogens.

AB - Major scientific obstacles blocking the development of a successful preventive HIV vaccine are the extraordinary variability of HIV, the lack of an exact animal model of HIV-induced AIDS, and the lack of understanding of the correlates of positive immunity to HIV. Current HIV vaccines containing the HIV gp120 envelope have been tested in phase I and II trials but they have had a major limitation of neutralizing only T-cell tropic laboratory-adapted HIV strains grown in T-cell lines, but not neutralizing HIV primary isolates. Phase III trials of monovalent HIV gp120 envelope vaccines are being planned in the US and Thailand, but concern has been raised that recombinant monovalent gp120 may not be an appropriate immunogen for an efficious HIV vaccine. Because the immune response is probably responsible for controlling the viral load in some long-term suvivors of HIV infection, studies are now being carried out to induce similar immunity against a broad spectrum of strains of HIV primary isolates with targeted HIV experimental immunogens.

KW - AIDS

KW - Animal models

KW - Immunization

KW - Pathogenesis

UR - http://www.scopus.com/inward/record.url?scp=0030041957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030041957&partnerID=8YFLogxK

M3 - Article

C2 - 8932504

AN - SCOPUS:0030041957

VL - 28

SP - 39

EP - 41

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 1

ER -